Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit

Abstract

AbstractImmune checkpoint inhibitor discovery represents a turning point in cancer treatment. However, the response rates of solid tumors remain ~10%–30%; consequently, prognostic and immune‐related adverse event (irAE) predictors are being explored. The programmed cell death protein 1 (PD‐1) receptor occupancy (RO) of PD‐1 inhibitors depends on the number of peripheral blood lymphocytes and their PD‐1 expression levels, suggesting that the RO may be related to efficacy and adverse events. As PD‐1 inhibition affects each T‐cell subset differently, the RO of each cell population must be characterized. However, relevant data have not been reported, and the prognostic relevance of this parameter is not known. In this study, we aimed to clarify the association between the nivolumab RO in each T‐cell population and patient prognosis and reveal the development of irAEs in nivolumab‐treated patients. Thirty‐two patients were included in the study, and the mean follow‐up period was 364 days. The nivolumab RO on effector regulatory T cells (eTregs) was significantly lower in the group that presented clinical benefits, and a significant negative association was observed between PD‐1 occupancy on eTregs and all‐cause mortality. The results suggest that the nivolumab RO on eTregs may be a prognostic factor in PD‐1 inhibitor therapy, implying that the inhibition of PD‐1/PD‐ligand 1 (PD‐L1) signaling on eTregs may attenuate antitumor effects.